Head-to-head LATITUDE Atlas data showed zasocitinib demonstrated statistical superiority to deucravacitinib across the primary and all key secondary efficacy endpoints with higher rates of complete ...
Our sustainability reporting is updated regularly and aligned with our policies, practices and data. We continue to improve our data collection processes and reporting of environmental, social and ...
 in Clinical Trials Compared to Those on Placebo As a ...
FY2025 Pipeline Successes Set the Stage for Pivotal Product Launches Achieved Latest FY2025 Management Guidance Takeda is Entering a New Era & Transforming for Growth Acceleration OSAKA, Japan, May 13 ...
Solid first quarter performance broadly in line with guidance, underpinned by resilient demand across core in-line brands Commercial execution and late-stage pipeline investments on schedule, ...
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus ...
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with ...
The four-year artificial intelligence (AI) program demonstrates how ‘a true spirit of collaboration’ can lead to breakthroughs in drug research and development. *The four-year artificial intelligence ...
Revenue Decline of 3.7% at Constant Exchange Rate (CER); 8.4% Decline at Actual Exchange Rates (AER) as VYVANSE® Generic Erosion Impacts Revenue in Line With Company Expectations Core Operating Profit ...
# Takeda Announces Changes to Organizational Structure and Executive Leadership Team for Fiscal Year 2026 to Fuel Speed, Competitiveness and Future Growth “Underpinned by strong values and purpose, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results